Bill & Melinda Gates Foundation

Likarda is a biotechnology company focused on developing innovative cell therapies and delivery technologies. Utilizing its patented Core-Shell Spherification® platform, Likarda specializes in cell encapsulation within biocompatible hydrogels, such as Hyaluronic Acid and PEG, which allows for customized delivery solutions tailored to the unique specifications of various cell therapies. The company's approach enables the creation of microcapsules that can provide injectable treatments with enhanced localization and efficacy or offer immunoprotective barriers for long-term cell transplants. Likarda is actively working on therapies for diabetes and osteoarthritis, including the delivery of islet-like cells for diabetes treatment and the slow-release injection of encapsulated stem cells for alleviating joint pain and reversing osteoarthritis degradation. The company has achieved significant recognition, including being named one of the "50 Most Promising Start-Ups in the World." To date, Likarda has secured over $8 million in funding through private investments, grants, and contract services.

Synvect is a biotechnology company that develops innovative solutions to control mosquito populations, with a focus on eliminating disease-carrying mosquitoes. The company's core technology involves using clustered regularly interspaced short palindromic repeats (CRISPR) gene editing to sterilize mosquito eggs, thereby preventing the breeding of disease-transmitting mosquitoes. Synvect's services aim to suppress harmful mosquito populations, enabling researchers to focus on eradicating mosquito-borne illnesses through affordable and user-friendly biological methods.

Leinco Technologies is a company that specializes in the development of high-purity monoclonal antibodies, proteins, and various reagents specifically for the diagnostic and biopharmaceutical industries. They provide a range of services, including in vitro antibody and protein production, antibody conjugations, and cell banking. Leinco Technologies focuses on augmenting the early discovery process in life science research and diagnostics, as well as contributing to the innovative development of protein therapeutics. Their expertise in optimizing and adapting products enables clients to effectively meet their research and development needs.

ReciBioPharm operates as a biologics company. ReciBioPharm is a division of Recipharm.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the permanent modification of the human genome. This innovative approach enables scientists and clinicians to introduce therapeutic messages into the genome, offering a potential cure for diseases at their source. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics aims to address significant limitations in these areas, enhancing their applicability and effectiveness. Founded by Flagship Pioneering, the company is positioned to transform genetic medicine and improve patient care through its groundbreaking technology.

Dyadic International is a biotechnology company based in Jupiter, Florida, with a research and development center in the Netherlands. The company focuses on the discovery, development, manufacture, and sale of enzymes and proteins for various industries, including bioenergy, bio-based chemicals, and biopharmaceuticals. Dyadic's core technology is its patented C1 fungus, which enables the efficient production of industrial enzymes and proteins at scale. This platform allows for the discovery of novel genes and proteins and has been licensed to several third parties, including Abengoa Bioenergy, BASF, and Codexis, for non-pharmaceutical applications. Dyadic seeks to maximize the value of its technologies through licensing arrangements and collaborations, providing partners with the ability to manufacture and utilize the enzymes produced through its innovative processes.

Freya Biosciences is a clinical-stage company focused on women's health, with operations in Copenhagen and Boston. It specializes in developing microbial immunotherapies aimed at addressing significant unmet medical needs across various conditions. The company utilizes a proprietary platform to engineer and manufacture live microbes, ensuring their safety and efficacy for human use. Through this innovative approach, Freya Biosciences seeks to create new treatment options for a range of diseases, striving to make a meaningful impact in the healthcare sector.

PopVax is a biotechnology company that developing novel mRNA vaccines and therapeutics using computational protein design.

CanSino Biologics focuses on the R&D, manufacturing, and commercialization of vaccine products for human use. These vaccine products include pneumococcal polysaccharide and conjugate vaccines, and a DTcP-based combo, and other items. It is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine.

Eyam Vaccines and Immunotherapeutics is a life science company focused on the research and development of vaccines aimed at combating infectious diseases. The company specializes in creating vaccines that target the spike glycoprotein protein, which generates neutralizing antibodies against the novel coronavirus. Eyam utilizes a self-amplifying vaccine platform designed to produce low-dose vaccines that offer advanced targeting capabilities for broad coverage and protection, addressing both current and emerging variants. By prioritizing the development of innovative vaccine solutions, Eyam aims to meet critical healthcare needs in the face of evolving infectious threats.

Schrödinger is a healthcare-focused software company that specializes in computational drug design, serving pharmaceutical and biotechnology research sectors. Established in 1990, it offers a powerful computational platform that aids biopharmaceutical and industrial companies, as well as academic and government institutions, in their research efforts globally. Schrödinger operates through two main segments: Software and Drug Discovery. The Software segment supplies solutions aimed at enhancing the drug discovery process across the life sciences and materials science industries. Meanwhile, the Drug Discovery segment generates revenue through a portfolio of preclinical and clinical programs, both independently and through collaborative efforts. The company is committed to advancing science and talent to support its platform and has over 400 employees, engaging with customers and collaborators in more than 70 countries.

Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, focusing on the development of CRISPR technology for the treatment of microbial diseases. Established in 2017, the company aims to revolutionize how such diseases are addressed by leveraging the adaptive immune system to create medicines that selectively target and eliminate harmful bacteria based on their specific DNA sequences. By utilizing a novel approach that subverts elements of the endogenous bacterial CRISPR machinery, Snipr Biome provides health professionals with innovative tools for targeted microbiome engineering, enhancing the precision and effectiveness of treatments for bacterial infections.

Nanite is a biotechnology company focused on non-viral gene delivery through the development of programmable polymer nanoparticles. Utilizing an artificial intelligence-driven platform, Nanite combines advanced high-throughput experimental and computational methods to create tailored delivery vehicles. These vehicles are designed to effectively transport a wide range of genetic materials with specific targeting capabilities, facilitating research in functional chemistry and enhancing the design of therapeutically relevant gene delivery systems.

Surf Bio is a preclinical biopharmaceutical company focused on developing innovative therapeutic solutions using a novel biotechnology platform. This platform centers around a next-generation surfactant designed to enhance drug effectiveness for a variety of medical conditions, including diabetes, oncology, infectious diseases, and gene therapy. By improving therapeutic applications, Surf Bio aims to provide healthcare organizations worldwide with access to new and more effective treatments for patients facing critical health issues.

Corner Therapeutics is a biotechnology research company focused on immunotherapy. It specializes in developing technologies that stimulate exceptional memory T cells to achieve lifelong immunity. The company utilizes a versatile dendritic cell hyperactivation platform that induces strong T-cell responses, aiming to provide robust and durable immunity against a wide range of cancers and infectious diseases. By enhancing T-cell activation, Corner Therapeutics seeks to enable healthcare providers to promote lasting immunity and optimize immune regulation.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Phase Genomics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing innovative technology for genome assembly and metagenome deconvolution, focusing on its ProxiMeta Hi-C platform. This platform empowers researchers in various fields, including agriculture, human health, and industrial biology, by enabling the cultivation-independent assembly of bacterial genomes. By exploiting the structure of DNA, Phase Genomics aims to provide scientists with the most complete and accurate genomes and metagenomes possible, facilitating transformative discoveries and advancements in their respective areas of study.

PhaSER Biomedical is Exploiting the 8HUM mouse, a unique mouse model with multiple utilities in drug discovery, and development.

ProteinLogic’s ImmiPrint® technology impacts the emerging market for diagnostic, predictive, prognostic and other biomarker applications.

C16 Biosciences, Inc. is a biotechnology company based in New York, established in 2017, specializing in the production of sustainable alternatives to palm oil through microbiology and fermentation processes. The firm focuses on creating innovative ingredients for food manufacturers, refiners, and consumers, aiming to decarbonize the supply chains of consumer product brands. C16 Biosciences has developed the Palmless™ platform, which features its first biodesigned ingredient, Torula oil—a premium bioactive oil known for its clinically proven benefits for skin and hair health. By leveraging biomanufacturing techniques, the company provides scalable and sustainable options, addressing the demand for environmentally friendly alternatives in the oil and fat market.

Sail Biomedicines is a biotechnology company developing innovative medicines using circular RNA technology and programmable nanoparticles. Its platform, Endless RNA (eRNA), combined with unique, naturally-derived nanoparticles, enables the comprehensive programming of drugs, enhancing their potency and targeting capabilities. The company aims to transform patient care by leveraging artificial intelligence and advanced delivery systems to create first-in-class therapeutics.

Brightseed, Inc. is a biotechnology company based in San Francisco, California, that specializes in the discovery of bioactive compounds in plants to enhance human health. Utilizing its advanced Forager platform, which employs artificial intelligence and machine learning algorithms, Brightseed accelerates the identification and validation of clinically beneficial molecules. This innovative approach enables the company to uncover connections between natural compounds and health outcomes, revealing the potential of bioactives that have previously remained uncharted. By integrating these discoveries back into the food supply chain, Brightseed collaborates with various companies across the consumer health continuum to develop science-backed health solutions aimed at managing chronic diseases and improving overall quality of life. Founded in 2017, Brightseed is committed to exploring the untapped resources of the plant kingdom to address pressing health challenges.

Molecular Loop is a biotechnology company focused on DNA sequencing. It offers a unique approach to sequencing through its Molecular Loop targeting technology, which eliminates the need for a separate library preparation process. The company's method involves designing amplicons that tile across each target on both strands, providing sequence data with minimal additional work and cost. Molecular Loop also provides custom assays tailored to user specifications, alongside expanded and customizable carrier screening panels and SARS-CoV-2 research panels. This enables healthcare professionals and researchers to access efficient systems for production-scale targeted sequencing applications.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Naobios is a contract development and manufacturing organization (CDMO) located in Saint Herblain, France. The company specializes in bioprocess development and provides good manufacturing practice (GMP) production services for clinical batches of various biopharmaceutical products, including viral vaccines, oncolytic viruses, viral vectors, and challenge agents. Naobios assists clients in the development and optimization of processes necessary for generating live vaccine products, ensuring compliance with industry standards.

BiomEdit is an innovation company focused on developing novel probiotics and microbiome-derived bioactives to enhance animal health. The company aims to tackle significant challenges in animal agriculture and food security by harnessing the potential of the microbiome. Utilizing a unique platform that incorporates high-throughput sequencing and data analytics, BiomEdit rapidly discovers and screens new probiotic species and bioactive molecules. These innovations can be engineered for improved thermostability, increased production of beneficial metabolites, and expression of immune-modulating proteins. By creating next-generation products that promote animal health without relying on antibiotics, BiomEdit addresses critical needs in livestock production and disease management.

STRM.BIO is a biotechnology company focused on enhancing gene therapy delivery through the use of extracellular vesicles (EVs). These natural carriers, which transport nucleic acids and proteins, offer innate targeting capabilities and can be mass-produced efficiently. By leveraging EVs, STRM.BIO aims to create a new class of therapeutics that not only introduces novel treatments but also improves the effectiveness of existing therapies. The company's approach seeks to simplify and enhance the safety of gene therapy delivery directly to patients, fulfilling the potential of this innovative medical field.

Bactolife is a company dedicated to addressing the global challenge of antimicrobial resistance through innovative solutions. Its proprietary Binding Protein ingredients are designed to strengthen the gut microbiome and minimize the risk of gastrointestinal infections in both humans and animals. By focusing on neutralizing harmful pathogens and their toxins while preserving beneficial microbes, Bactolife aims to enhance gut health and reduce reliance on traditional antimicrobials. The company's approach emphasizes the modulation of the gut microbiome to improve overall health outcomes, making a significant contribution to the fight against antimicrobial resistance. Through its developments, Bactolife seeks to empower individuals and communities worldwide in maintaining better health.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Aphea.Bio focuses on developing innovative agricultural products aimed at enhancing crop health and yields. The company specializes in creating next-generation biopesticides derived from natural microorganisms, which serve as sustainable alternatives to traditional chemical pesticides facing regulatory challenges. Additionally, Aphea.Bio produces biostimulants that promote crop growth by enhancing nutrient uptake from the soil. Utilizing proprietary technologies, the company is dedicated to discovering new biocontrol and biostimulant products that help farmers sustainably manage fungal diseases, pests, and weeds, ultimately improving crop productivity and environmental health.

Latham BioPharm Group (LBG) specializes in providing comprehensive support for the life sciences sector, focusing on advancing programs through a range of services that include business development, program management, quality assurance, regulatory guidance, and strategic consulting. With a team averaging over 20 years of experience, many of whom have held senior positions in both private enterprises and the US government, LBG has a proven track record in biodefense, pandemic response, and product development. Over the past two decades, the firm has successfully helped clients secure more than $1 billion in government funding and over $100 million in licensing fees. Their services encompass critical business evaluations, market assessments, and assistance in obtaining funding, followed by effective program management to drive projects toward key milestones. By integrating expertise in vaccine, therapeutic, medical device, and diagnostic product development, LBG aids clients in achieving their organizational objectives efficiently and effectively.

Aegis Life is a biotechnology company focused on advancing nucleic acid delivery technology, specifically through its proprietary platform known as fusogenix PLV. This technology, developed over two decades, is designed to facilitate the rapid development and commercialization of vaccines and therapeutics aimed at preventing and treating infectious diseases. Aegis Life's innovative approach supports the pharmaceutical industry in accelerating the discovery, clinical development, and manufacturing processes for vaccines and treatments, particularly in response to emerging health threats such as COVID-19.

The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines using a proprietary technology known as molecular superglue. This platform allows for the rapid creation of bonding vaccines by attaching antigens to viruses and other particles, enhancing the vaccine development process. By leveraging this unique approach, SpyBiotech aims to provide medical institutions and research centers with more effective vaccines that can be developed in a shorter timeframe, ultimately improving immunity against various diseases, including bacterial infections.

UW Medicine is a clinical research and healthcare system that provides a higher degree of healthcare for pre-med students. UW Medicine health professionals provide the most up-to-date care for each individual patient through these integrated programs, lead one of the world's largest and most comprehensive medical research programs, and provide innovative learning programs for students, trainees, and practitioners in the health professions. UW Medicine, as the region's only comprehensive clinical, research, and learning health system, provides a higher level of healthcare, ranging from primary and preventive care to the most highly specialized care for the most complex medical conditions.

Touchlight Genetics Ltd. is a biotechnology company based in Leatherhead, United Kingdom, specializing in DNA therapies and technology. Founded in 2007, it has developed the proTL synthetic DNA platform, which allows for the production of doggybone closed linear DNA without the need for bacterial fermentation. This innovative approach supports various applications, including veterinary vaccines, monoclonal antibodies, cancer and gene therapies, allergy treatments, RNA interference therapies, and stem cell reprogramming. The company boasts a skilled scientific and drug development team, led by founder and CEO Jonny Ohlson, and includes experienced professionals such as Clive Dix and John Tite. Touchlight has established partnerships with several leading academic institutions, including Imperial College London and the University of Pennsylvania, to advance its research and development efforts. The company has successfully patented its synthetic DNA platform and demonstrated therapeutic proof-of-principle through collaboration with these academic partners.

Bayer is a multinational corporation with a focus on life science industries. It operates in three main business areas: Pharmaceuticals, Consumer Health, and Crop Science. Bayer Pharmaceuticals develops and markets a wide range of medicines, including those for cardiovascular diseases, oncology, and women's health. The Consumer Health division offers over-the-counter products and medical devices, while Crop Science provides crop protection products, seeds, and digital farming solutions. Bayer Animal Health, a part of the Crop Science division, is a global leader in animal health, offering a broad portfolio of products for the treatment and prevention of diseases in livestock and companion animals. The company's global presence and extensive product portfolio enable it to address various health challenges in humans, animals, and crops, contributing to a sustainable future.

Adapsyn Bioscience Inc. is a biotechnology company based in Hamilton, Canada, focused on the discovery and development of novel medicines derived from organic biomolecules, particularly those produced by microorganisms. Founded in 2016, the company utilizes an advanced bioinformatics platform that incorporates proprietary algorithms and artificial intelligence to analyze genomic and metabolomic data. Its key products include various tools such as PRISM, which identifies biosynthetic gene clusters in microbial genomes; GARLIC, which defines gene clusters for natural product drug variants; the GRAPE algorithm, which reveals evolved drug fragments; and CLAMS, which matches gene clusters to compounds identified through mass spectrometry. By leveraging these innovative technologies, Adapsyn aims to uncover small molecules with unique biological activities, thereby enhancing drug discovery efforts in the biotechnology and pharmaceutical sectors.

Manus Bio Inc. is a biotechnology company that specializes in recreating plant processes in microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a combination of metabolic engineering, protein engineering, and systems biology to develop microbes capable of generating a variety of plant-based ingredients. These ingredients have diverse applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. Manus Bio operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. The company was previously known as Manus Biosynthesis, Inc. before changing its name in June 2018.

Bactolife is a company dedicated to addressing the global challenge of antimicrobial resistance through innovative solutions. Its proprietary Binding Protein ingredients are designed to strengthen the gut microbiome and minimize the risk of gastrointestinal infections in both humans and animals. By focusing on neutralizing harmful pathogens and their toxins while preserving beneficial microbes, Bactolife aims to enhance gut health and reduce reliance on traditional antimicrobials. The company's approach emphasizes the modulation of the gut microbiome to improve overall health outcomes, making a significant contribution to the fight against antimicrobial resistance. Through its developments, Bactolife seeks to empower individuals and communities worldwide in maintaining better health.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

Enko Chem, Inc. is a biotechnology company based in Woburn, Massachusetts, that focuses on discovering and developing innovative small-molecule products designed to protect crops from pests and diseases. Founded in 2017, the company utilizes a proprietary technology platform that enables the rapid identification of safe and cost-effective solutions aimed at promoting sustainable food production. Through its efforts, Enko Chem seeks to address the challenges faced by farmers in maintaining crop health while ensuring environmental sustainability.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

Phase Genomics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing innovative technology for genome assembly and metagenome deconvolution, focusing on its ProxiMeta Hi-C platform. This platform empowers researchers in various fields, including agriculture, human health, and industrial biology, by enabling the cultivation-independent assembly of bacterial genomes. By exploiting the structure of DNA, Phase Genomics aims to provide scientists with the most complete and accurate genomes and metagenomes possible, facilitating transformative discoveries and advancements in their respective areas of study.

Cardea Bio, Inc. is a biotechnology company based in San Diego, California, focused on developing and commercializing bioelectronics for research and diagnostics. Established in 2013, Cardea utilizes proprietary graphene-based digital biosensors to create advanced biosensor hardware, software, and molecular infrastructure, enabling precision healthcare through improved diagnostic capabilities. The company's product offerings include the AGILE R100, an innovative assay for drug discovery, and the AGILE R200, an automated high-throughput screening solution. Cardea's biosensors convert biomolecular interactions into digital data, allowing for real-time biological signal analysis and access to streaming multi-omics data. Their solutions cater to various applications in life sciences and healthcare, such as small molecule validation, antibody characterization, and biomolecular analysis.

Yemaachi Biotechnology is focused on advancing the diagnosis and treatment of cancer through innovative therapeutic technologies. The company employs immunogenomics, bioinformatics, and artificial intelligence to enhance the development of effective cancer detection and treatment strategies. By leveraging these advanced methodologies, Yemaachi aims to lower the economic burden of cancer and improve patient outcomes through more accurate and efficient therapeutic solutions.

Elarex, a Canadian healthcare technology company, specializes in developing and commercializing proprietary formulation technologies. Its flagship innovation, PT120, stabilizes biologicals, including live vaccines, enabling them to maintain full efficacy even when stored at 40°C, comparable to -80°C storage. This breakthrough allows for broader access to vaccines and biological drugs by facilitating transportation and storage in diverse environments, thereby enhancing global healthcare accessibility.

Providence Therapeutics Inc. is a biotechnology company based in Toronto, Canada, founded in 2015. The company specializes in the development and production of messenger ribonucleic acid (mRNA) vaccines formulated in lipid nanoparticles. Its portfolio includes PTX-101, a personalized mRNA cancer vaccine aimed at treating advanced ovarian cancer, and various COVID-19 vaccines, including PTX-COVID19-B and PTX-COVID19-T, which target the coronavirus and elicit immune responses against the virus. Providence Therapeutics is committed to creating safe and effective therapies to address unmet medical needs, particularly in oncology and infectious diseases, thereby enhancing the quality of life for patients.

Schrödinger is a healthcare-focused software company that specializes in computational drug design, serving pharmaceutical and biotechnology research sectors. Established in 1990, it offers a powerful computational platform that aids biopharmaceutical and industrial companies, as well as academic and government institutions, in their research efforts globally. Schrödinger operates through two main segments: Software and Drug Discovery. The Software segment supplies solutions aimed at enhancing the drug discovery process across the life sciences and materials science industries. Meanwhile, the Drug Discovery segment generates revenue through a portfolio of preclinical and clinical programs, both independently and through collaborative efforts. The company is committed to advancing science and talent to support its platform and has over 400 employees, engaging with customers and collaborators in more than 70 countries.

Brightseed, Inc. is a biotechnology company based in San Francisco, California, that specializes in the discovery of bioactive compounds in plants to enhance human health. Utilizing its advanced Forager platform, which employs artificial intelligence and machine learning algorithms, Brightseed accelerates the identification and validation of clinically beneficial molecules. This innovative approach enables the company to uncover connections between natural compounds and health outcomes, revealing the potential of bioactives that have previously remained uncharted. By integrating these discoveries back into the food supply chain, Brightseed collaborates with various companies across the consumer health continuum to develop science-backed health solutions aimed at managing chronic diseases and improving overall quality of life. Founded in 2017, Brightseed is committed to exploring the untapped resources of the plant kingdom to address pressing health challenges.

Reithera Srl is a company devoted to develop and produce biopharmaceutical products based on gene delivery technologies for advanced therapies, in order to prevent and treat several serious or life-threatening diseases.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland, dedicated to developing transformative gene-based medicines for serious human diseases using CRISPR/Cas9 technology. This revolutionary gene-editing platform allows for precise changes to genomic DNA. The company's portfolio includes therapeutic programs targeting hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Their lead product candidate is CTX001, a gene-edited therapy for transfusion-dependent beta thalassemia or severe sickle cell disease, which has been approved as Casgevy in collaboration with Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing CTX110, an allogeneic CAR-T therapy targeting CD19-positive malignancies, and other programs like CTX120 for multiple myeloma and CTX130 for solid tumors and hematologic malignancies. The company also engages in regenerative medicine programs for diabetes and genetic disease treatments such as glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. CRISPR Therapeutics has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines using its innovative virus-like particle (VLP) technology platform, which allows for the multivalent display of complex viral antigens. This technology aims to provide broad and durable protection against various infectious diseases, with an initial focus on life-threatening respiratory illnesses. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2. The company is dedicated to advancing its VLP technology to discover, develop, and ultimately commercialize effective vaccines against these infectious diseases.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Enko Chem, Inc. is a biotechnology company based in Woburn, Massachusetts, that focuses on discovering and developing innovative small-molecule products designed to protect crops from pests and diseases. Founded in 2017, the company utilizes a proprietary technology platform that enables the rapid identification of safe and cost-effective solutions aimed at promoting sustainable food production. Through its efforts, Enko Chem seeks to address the challenges faced by farmers in maintaining crop health while ensuring environmental sustainability.

Inovio Pharmaceuticals, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of DNA medicines aimed at treating, curing, and protecting individuals from diseases related to human papillomavirus (HPV), cancer, and infectious diseases. The company's innovative SynCon immunotherapy design enables the immune system to target cancerous cells while providing cross-strain protection against various pathogens. Inovio's clinical studies focus on HPV-associated precancers, cancers, and other disorders, as well as diseases such as glioblastoma multiforme, HIV, and COVID-19. The company has developed a proprietary delivery system that allows DNA medicine to be introduced directly into cells, producing a strong immune response. Notably, its lead candidate, VGX-3100, is undergoing Phase 3 trials for precancerous cervical dysplasia, having shown promise in earlier trials by effectively clearing high-risk HPV strains. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio collaborates with various partners, including major pharmaceutical companies and research institutions, to advance its clinical initiatives and expand its therapeutic reach.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, focused on enhancing global health outcomes through early disease detection. The company has developed a proprietary technology platform that enables the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This platform facilitates the analysis of native-state biomarkers and nanoparticles, supporting multiomics applications. Biological Dynamics specializes in cancer detection and offers a range of services, including the TR(ACE) Assay for monitoring treatment responses and tumor burdens, as well as liquid biopsy testing for personalized medicine. Additionally, the company provides clinical laboratory services, including molecular and next-generation sequencing, and has programs aimed at drug development in areas such as Alzheimer's disease. Founded in 2008, Biological Dynamics is committed to utilizing machine learning and its advanced technology to address various health challenges, including autoimmune diseases, transplant rejection, and traumatic brain injury.

RJH Biosciences is a biotechnology company specializing in the development of transfection reagents and delivery systems designed to transport various types of nucleic acids into human cells and cell lines. The company emphasizes innovative solutions for addressing blood cancers and modifying immune cells, thereby enhancing the therapeutic potential of nucleic acids in medical applications. RJH Biosciences distributes its products through its website and is also engaged in projects aimed at developing new medical treatments.

One.bio is a biotechnology spinout from UC Davis that specializes in developing naturally-derived oligosaccharides for applications in food, agriculture, and biopharmaceuticals. Utilizing proprietary technology, the company creates innovative ingredients aimed at modulating the microbiome and enhancing immune function. This focus allows One.bio to provide clients with access to novel prebiotics and therapies that support both human and animal health. By unlocking the benefits of nutrition, One.bio aims to contribute to improved longevity and overall well-being.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

BioNTech is a Germany-based biotechnology company that specializes in developing innovative immunotherapies for cancer and other serious diseases, as well as vaccines for infectious diseases, including COVID-19. The company’s oncology pipeline includes a range of drug classes, such as mRNA-based drugs that encode antigens and neoantigens, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech has established partnerships with several major pharmaceutical companies, enhancing its research and development capabilities. Its COVID-19 vaccine, Comirnaty, represents its first commercialized product, demonstrating the company's commitment to addressing urgent health challenges through advanced therapeutic approaches.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, focused on enhancing global health outcomes through early disease detection. The company has developed a proprietary technology platform that enables the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This platform facilitates the analysis of native-state biomarkers and nanoparticles, supporting multiomics applications. Biological Dynamics specializes in cancer detection and offers a range of services, including the TR(ACE) Assay for monitoring treatment responses and tumor burdens, as well as liquid biopsy testing for personalized medicine. Additionally, the company provides clinical laboratory services, including molecular and next-generation sequencing, and has programs aimed at drug development in areas such as Alzheimer's disease. Founded in 2008, Biological Dynamics is committed to utilizing machine learning and its advanced technology to address various health challenges, including autoimmune diseases, transplant rejection, and traumatic brain injury.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Manus Bio Inc. is a biotechnology company that specializes in recreating plant processes in microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a combination of metabolic engineering, protein engineering, and systems biology to develop microbes capable of generating a variety of plant-based ingredients. These ingredients have diverse applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. Manus Bio operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. The company was previously known as Manus Biosynthesis, Inc. before changing its name in June 2018.

Phase Genomics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing innovative technology for genome assembly and metagenome deconvolution, focusing on its ProxiMeta Hi-C platform. This platform empowers researchers in various fields, including agriculture, human health, and industrial biology, by enabling the cultivation-independent assembly of bacterial genomes. By exploiting the structure of DNA, Phase Genomics aims to provide scientists with the most complete and accurate genomes and metagenomes possible, facilitating transformative discoveries and advancements in their respective areas of study.

Schrödinger is a healthcare-focused software company that specializes in computational drug design, serving pharmaceutical and biotechnology research sectors. Established in 1990, it offers a powerful computational platform that aids biopharmaceutical and industrial companies, as well as academic and government institutions, in their research efforts globally. Schrödinger operates through two main segments: Software and Drug Discovery. The Software segment supplies solutions aimed at enhancing the drug discovery process across the life sciences and materials science industries. Meanwhile, the Drug Discovery segment generates revenue through a portfolio of preclinical and clinical programs, both independently and through collaborative efforts. The company is committed to advancing science and talent to support its platform and has over 400 employees, engaging with customers and collaborators in more than 70 countries.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Lyell Immunopharma Inc is a clinical-stage cell therapy company focused on developing innovative treatments for patients with solid tumors through T cell reprogramming. The company aims to overcome significant challenges in adoptive T cell therapy, specifically T cell exhaustion and loss of durable stemness, which impede effective and lasting responses in cancer treatment. Utilizing its proprietary platforms, Gen-R and Epi-R, Lyell is working to enhance the proliferative capacity, self-renewal, and differentiation abilities of T cells. The company's product pipeline includes several candidates, such as LYL797, LYL119, and LYL845, all designed to deliver improved and potentially curative outcomes for patients suffering from solid tumors.

Evolve Biosystems, Inc. is a biotechnology company based in Davis, California, focused on developing and marketing probiotic-based biotherapeutics aimed at establishing, restoring, and maintaining a healthy human microbiome. The company specializes in addressing gut dysbiosis across the human life cycle, particularly in newborns during their first six months of life. Evolve Biosystems utilizes a platform that combines specific probiotic bacteria with prebiotic oligosaccharides to create effective delivery systems. Their products include consumer-directed solutions for home use as well as specialized formulations for neonatal intensive care units. In addition to human health, the company also applies its discovery platform to address similar microbiome issues in production animals. Evolve Biosystems was incorporated in 2011.

Manus Bio Inc. is a biotechnology company that specializes in recreating plant processes in microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a combination of metabolic engineering, protein engineering, and systems biology to develop microbes capable of generating a variety of plant-based ingredients. These ingredients have diverse applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. Manus Bio operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. The company was previously known as Manus Biosynthesis, Inc. before changing its name in June 2018.

Immunethep is a biotechnology company focused on developing innovative therapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company leverages proprietary technology to address significant unmet medical needs. Immunethep has identified a novel mechanism by which various pathogenic bacteria suppress the host immune response. By targeting this mechanism, the company aims to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, Immunethep is working on neonatal vaccines designed to protect infants from bacterial infections before birth, thereby enhancing their immunity and preventing multi-bacterial infections. Through these advancements, Immunethep strives to improve patient outcomes and contribute to the field of advanced healthcare.

Ventria Bioscience, Inc. is a biotechnology company based in Fort Collins, Colorado, specializing in the development, manufacturing, and marketing of health and nutrition products. Founded in 1993, the company focuses on human nutrition and therapeutics, offering a range of products that includes lactoferrin and lysozyme glycoproteins, which are utilized for gastrointestinal health and the dietary management of acute diarrhea, as well as for treating topical infections and fungal conditions. Ventria also provides OptiVERO, a specialized cell culture media for vaccine manufacturing, and operates a BioShare program that grants researchers access to recombinant proteins and peptides for various research applications. The company leverages its patented ExpressTec technology, which enhances recombinant protein yield through a plant-based manufacturing process, enabling the development of new biotherapeutics, vaccines, and other biomanufacturing reagents.

PnuVax Incorporated is dedicated to the production of high quality biopharmaceuticals for the promotion of public health worldwide. Their team has over 30 years of experience in the pharmaceutical industry, from research to full scale production.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Vaxess Technologies, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2011. The company focuses on developing and commercializing innovative silk biomaterial technologies. Its key product, the MIMIX microneedle platform, facilitates the transdermal delivery of vaccines and therapeutics. This sustained release patch technology allows for a controlled release of vaccines, mimicking the natural infection process to enhance immune response and effectiveness. Vaxess's patch is engineered for stability, eliminating the need for refrigeration, which enables shipping and application in low-resource settings. In addition to its vaccine delivery systems, Vaxess is also engaged in creating novel therapies aimed at oncology care and infectious diseases, ultimately striving to improve patient outcomes with reduced treatment burdens.

Danforth Technology Company (DTC) is a venture builder based in St. Louis, Missouri, and operates as a subsidiary of the Donald Danforth Plant Science Center. Its primary role is to facilitate the early-stage development of startup companies that leverage technologies developed by the Center's scientists. DTC focuses on moving scientific discoveries into the marketplace more efficiently by providing intellectual property development, licensing, and entrepreneurship support. The company also offers seed funding and early management assistance to promising startups, enhancing the potential for innovation in plant science and contributing to broader societal goals such as improving human health and environmental sustainability.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

Mologic Ltd. is a UK-based company specializing in the development of diagnostic products primarily for the research market. Founded in 2003 by a father-son team, the company is committed to enhancing patient care and advancing research in various fields, including clinical research, diagnostic development, and wound care. Mologic offers a range of diagnostic tools, such as lateral flow kits for measuring Alpha-1 antitrypsin and desmosine in urine, as well as fMLP assay kits for detecting fMLP in human urine. In addition to its product offerings, the company provides services in assay and reagent development, clinical evaluation studies, and the creation of high-performance antibodies for challenging targets. Mologic aims to make significant contributions to healthcare and education through its innovative research and development efforts.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Batavia Biosciences is a biotechnology company that specializes in accelerating the development of biopharmaceutical products, including viral and bacterial vaccines, recombinant proteins, antibodies, and gene therapy products. The company offers a comprehensive range of services that encompass candidate selection, production of research materials, and both upstream and downstream process development. Additionally, Batavia Biosciences provides assay development, product characterization, and clinical manufacturing. By leveraging unique technologies such as STEP® protein expression technology and SCOUT® high throughput process technology, the company aims to enhance the efficiency and cost-effectiveness of the early stages of product development. This focus allows Batavia Biosciences to help clients complete their preclinical phases more quickly while improving the likelihood of success in transitioning to clinical trials.

Just Evotec Biologics, founded in 2014 and acquired by Evotec in 2019, specializes in the development of biotherapeutic technologies aimed at enhancing global access to biotherapeutics. The company focuses on innovative and integrated technologies that streamline the design, development, and manufacturing processes of biologics. Its key strengths lie in antibody discovery, molecular design, and the design of manufacturing processes and facilities. By leveraging scientific expertise and machine learning-driven technologies, Just Evotec Biologics provides clients with comprehensive solutions that accelerate biotherapeutic development while significantly lowering manufacturing costs.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company founded in 2016 and based in Hangzhou, China. The company focuses on the development of antibody and recombinant protein bio-therapeutics, utilizing advanced molecular and process design techniques. As a subsidiary of MabSpace Biosciences Co., Ltd., Hangzhou Just Biotherapeutics aims to overcome scientific and technical challenges in the field of biologics. Their innovative technology enhances the development process for bio-medicine while significantly lowering manufacturing costs, thereby accelerating the availability of therapeutic solutions.

Takeda Ventures, established in 2001, is the venture capital arm of Takeda Pharmaceutical Company Limited. Based in Cambridge, Massachusetts, with additional offices in San Diego, California, and globally, the firm specializes in direct and fund-of-fund investments, focusing on seed to mid-stage biotechnology and pharmaceutical companies. Takeda Ventures invests in therapeutics, including cardiovascular, inflammatory, metabolic, and oncological diseases, as well as regenerative medicines and novel technologies like RNA and DNA modulation. It typically invests between $0.25 million to $5 million, preferring minority stakes and board observer roles, and co-invests with other venture capital firms. Additionally, Takeda Ventures facilitates preclinical therapeutic discovery alliances and invests in digital health companies that improve patient outcomes and care delivery.

Pivot Bio is a biotechnology company founded in 2010 and based in Emeryville, California, that focuses on enhancing crop nutrition through the use of engineered microbes. The company leverages its deep understanding of the plant microbiome, employing engineering principles and data science to map microbial dynamics and develop beneficial traits. Pivot Bio's proprietary ON Technology utilizes naturally occurring microbes to provide crops with essential nutrients, particularly nitrogen, which is crucial for growth. This innovative approach aims to replace synthetic nitrogen fertilizers, thereby reducing the environmental impact associated with conventional farming practices. By enhancing crops' ability to capture and metabolize atmospheric nitrogen, Pivot Bio seeks to lower farming costs, improve crop yields, and contribute to a sustainable agricultural future that benefits both the planet and food supply.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

Lodo Therapeutics Corporation is a drug discovery and development company dedicated to creating novel therapeutics derived from natural sources. It focuses on addressing significant health challenges, particularly resistant infectious diseases and cancers, by collaborating with global pharmaceutical companies and leading non-governmental organizations. Founded to realize the scientific vision of Dr. Sean Brady from Rockefeller University, Lodo Therapeutics utilizes a genome-based, culture-independent platform to discover and characterize small molecules sourced from environmental microbial DNA. This innovative approach leverages advancements in DNA sequencing and bioinformatics to explore the untapped potential of microbial evolution, aiming to identify therapeutically valuable pharmaceutical products. Headquartered in New York City at the Alexandria Center for Life Science, Lodo Therapeutics is committed to harnessing the power of nature in the fight against undruggable targets and high unmet medical needs.

Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumor types. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, characterized by a novel mechanism of action. ATRC-101 has demonstrated reactivity in vitro with a significant majority of human cancer samples, including ovarian, non-small cell lung, colorectal, and breast cancers. Atreca employs a unique technology to identify antibodies produced during immune responses without prior knowledge of antigens. The company collaborates strategically with Merck Sharp & Dohme Corp. to pinpoint antigenic targets of selected antibodies that may have applications in oncology. Founded in 2010, Atreca is dedicated to advancing innovative treatments for cancer.

CureVac is a clinical-stage biopharmaceutical company based in Germany, established in 2000, that specializes in developing vaccines and therapies utilizing messenger ribonucleic acid (mRNA). The company focuses on both prophylactic and therapeutic applications of mRNA, enabling the human body to produce proteins that combat various diseases. CureVac's innovative pipeline includes mRNA-based cancer immunotherapies, such as CV9104, which is in Phase IIb development for prostate cancer, as well as RNActive vaccines against infectious diseases and RNArt molecular therapies designed to stimulate the production of therapeutic proteins. Additionally, the company has collaborated with GSK to advance second-generation vaccines for seasonal influenza and COVID-19, alongside an avian influenza vaccine, while also exploring mRNA therapies for oncology and other conditions affecting the liver and eyes.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Ceres Nanosciences, Inc., established in 2008 and based in Manassas, Virginia, specializes in the research, development, and commercialization of innovative sample preparation products and diagnostic tests. The company's core technology, Nanotrap, captures, enriches, and preserves biomarkers from various biofluid matrices, facilitating early detection of diseases such as cancer, cardiac, and infectious diseases. Ceres' lead product is a direct antigen test for Lyme disease diagnosis, slated for commercial release in 2015. The company's product pipeline includes advanced sample collection technologies and diagnostics, funded through federal grants and industry collaborations.

Schrödinger is a healthcare-focused software company that specializes in computational drug design, serving pharmaceutical and biotechnology research sectors. Established in 1990, it offers a powerful computational platform that aids biopharmaceutical and industrial companies, as well as academic and government institutions, in their research efforts globally. Schrödinger operates through two main segments: Software and Drug Discovery. The Software segment supplies solutions aimed at enhancing the drug discovery process across the life sciences and materials science industries. Meanwhile, the Drug Discovery segment generates revenue through a portfolio of preclinical and clinical programs, both independently and through collaborative efforts. The company is committed to advancing science and talent to support its platform and has over 400 employees, engaging with customers and collaborators in more than 70 countries.